Karen Silence, PhD

Head Preclinical Product Development at argenx

Speaker

Karen worked for four years at the university of Brussels developing the Nanobody platform which lead to the establishment of Ablynx, where she was the first employee. She was inventor and project leader for Caplacizumab, the first and only Nanobody approved today. After that Karen joined argenx where she was project leader for ARGX-110, ARGX-117, ARGX-119 and ARGX-120. Currently she is heading all preclinical programs at argenx taking antibodies from lead optimisation until IND filing.